PMID- 33223841
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 13
DP  - 2020
TI  - Higher Serum Asprosin Level is Associated with Urinary Albumin Excretion and 
      Renal Function in Type 2 Diabetes.
PG  - 4341-4351
LID - 10.2147/DMSO.S283413 [doi]
AB  - AIM: We detected whether serum asprosin levels play a role in the occurrence and 
      development of albuminuria in patients with type 2 diabetes mellitus (T2DM), 
      which has not been previously discussed. METHODS: Based on urinary 
      albumin/creatinine ratio (UACR), 207 T2DM patients were divided into T2DM 
      patients with normoalbuminuria (UACR<30 mg/g), microalbuminuria (30</=UACR<300 
      mg/g), and macroalbuminuria (UACR>/=300 mg/g). Serum asprosin levels were 
      determined by enzyme-linked immunosorbent assay. RESULTS: Comparatively, the 
      serum asprosin levels in T2DM patient groups with macroalbuminuria [2.37 
      (1.63-3.57)] and microalbuminuria [2.10 (1.60-2.90)] were significantly increased 
      than the normoalbuminuria group [1.59 (1.18-2.09)] (P<0.001). Importantly, the 
      serum level of asprosin was positively correlated with UACR (r=0.304, P<0.001), 
      creatinine (r=0.157, P=0.024), blood urea nitrogen (BUN) (r=0.244, P<0.001), and 
      negatively with glomerular filtration rate (eGFR) (r=-0.159, P=0.022). 
      Furthermore, multiple stepwise regression analyses showed that asprosin was 
      significantly and independently related to UACR, BUN, DBP, and LDL-C (P<0.05). 
      Besides, after adjustment for the confounders, the serum asprosin level was 
      constantly and independently associated with the development of albuminuria in 
      T2DM patients [OR (95% CI): 2.003 (1.37~2.928), P <0.001]. CONCLUSION: Obviously, 
      the serum asprosin level was independently correlated with UACR in T2DM patients, 
      which implies circulating asprosin may play an essential role in the pathogenesis 
      of diabetic nephropathy.
CI  - (c) 2020 Deng et al.
FAU - Deng, Xia
AU  - Deng X
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Zhao, Li
AU  - Zhao L
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Guo, Chang
AU  - Guo C
AUID- ORCID: 0000-0003-3239-2080
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Yang, Ling
AU  - Yang L
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Wang, Dong
AU  - Wang D
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Li, Yanyan
AU  - Li Y
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Xia, Hong
AU  - Xia H
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Wang, Chenxi
AU  - Wang C
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Cai, Zhensheng
AU  - Cai Z
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Li, Lian
AU  - Li L
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Zhao, Zhicong
AU  - Zhao Z
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
FAU - Yuan, Guoyue
AU  - Yuan G
AD  - Department of Endocrinology, Affiliated Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu 212001, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20201113
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC7671462
OTO - NOTNLM
OT  - asprosin
OT  - diabetic nephropathy
OT  - type 2 diabetes mellitus
COIS- The authors declared no potential competing interests with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
PMCR- 2020/11/13
CRDT- 2020/11/23 05:36
PHST- 2020/09/22 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/11/23 05:36 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
PHST- 2020/11/13 00:00 [pmc-release]
AID - 283413 [pii]
AID - 10.2147/DMSO.S283413 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2020 Nov 13;13:4341-4351. doi: 10.2147/DMSO.S283413. 
      eCollection 2020.